Previous 10 | Next 10 |
2024-03-11 17:35:46 ET Major earnings expected after the bell on Tuesday include: Clover Health Investments, Corp. ( CLOV ) SurgePays ( SURG ) Heron Therapeutics ( HRTX ) Qifu Technology ( QFIN ) Veritone ( VERI ) Read the full article on Se...
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its fourth quarter and full year...
2024-02-25 13:37:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks . Of course, the excitement goes toward both ext...
2024-02-07 09:29:14 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript Clearside Biomedical reports progress in ODYSSEY Phase 2b trial of CLS-AX Seeking Alpha’s Quant Rating on Clearside Biomedical Histor...
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ®...
2024-01-22 11:42:05 ET More on Clearside Biomedical Clearside Biomedical reports progress in ODYSSEY Phase 2b trial of CLS-AX BioCryst, Clearside Biomedical in pact for diabetic eye disease Read the full article on Seeking Alpha For further details see: C...
2023-12-14 08:28:42 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript BioCryst, Clearside Biomedical in pact for diabetic eye disease Seeking Alpha’s Quant Rating on Clearside Biomedical Historical earni...
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS Microinjector ® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Dec. 14...
2023-11-13 19:18:08 ET Clearside Biomedical, Inc. (CLSD) Q3 2023 Results Conference Call November 13, 2023 04:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference Call Participants Serge Belanger - Need...
2023-11-13 16:10:45 ET More on Clearside Biomedical BioCryst, Clearside Biomedical in pact for diabetic eye disease Seeking Alpha’s Quant Rating on Clearside Biomedical Historical earnings data for Clearside Biomedical Financial information for Clearsi...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector ® - ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc....
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Curren...
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therap...